NCT07279740 Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia
| NCT ID | NCT07279740 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Sunnybrook Health Sciences Centre |
| Condition | Alzheimer s Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2026-01 |
| Primary Completion | 2027-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 12 participants in total. It began in 2026-01 with a primary completion date of 2027-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates whether the combined treatment of methylphenidate and non-invasive brain stimulation, called intermittent theta burst stimulation, can effectively treat apathy in individuals with Alzheimer's disease or mixed AD/vascular dementia
Eligibility Criteria
Inclusion Criteria: * Alzheimer's disease or mixed Alzheimer's disease and vascular disease * MMSE score 10-28 inclusive * Clinically significant apathy * Stable dose of psychotropic medication * Care partner must spend at least 10hrs/week with the participant Exclusion Criteria: * Major Depressive Episode * Clinically significant agitation, delusions, hallucinations * Currently talking a dopaminergic agent other than methylphenidate * Failure to clear the TMS adult safety scale (e.g. unapproved pacemakers, metallic implants, history of epilepsy) * Central nervous system abnormalities (other than Alzheimer's disease) deemed clinically significant by study physician or seizures * Any condition that in the opinion of the study physician, makes it medically unsafe for the patient to enroll in the trial
Contact & Investigator
Krista Lanctot, PhD
PRINCIPAL INVESTIGATOR
Sunnybrook Research Institute
Frequently Asked Questions
Who can join the NCT07279740 clinical trial?
This trial is open to participants of all sexes, studying Alzheimer s Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07279740 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07279740 currently recruiting?
Yes, NCT07279740 is actively recruiting participants. Visit ClinicalTrials.gov or contact Sunnybrook Health Sciences Centre to inquire about joining.
Where is the NCT07279740 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT07279740 clinical trial?
NCT07279740 is sponsored by Sunnybrook Health Sciences Centre. The principal investigator is Krista Lanctot, PhD at Sunnybrook Research Institute. The trial plans to enroll 12 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.